Evidence map›Paper›PMID 26078558›Full record

ReviewWorld journal of gastroenterology2015

Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 131 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Relationship betweenThe Journal of international medical research · 2021
    Article
  11. Statins for treatment of chronic liver disease.Current opinion in gastroenterology · 2021
    Review
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Vasilios G AthyrosVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
Konstantinos TziomalosVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
Niki KatsikiVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
Michael DoumasVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
Asterios KaragiannisVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
Dimitri P MikhailidisVasilios G Athyros, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 55132 Thessaloniki, Greece.
The Royal Free Hospital · GBAHEPA University Hospital · GRCreative Research Enterprises (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered to be an independent cardiovascular disease (CVD) risk factor. However, simple steatosis has a benign clinical course without excess mortality. In contrast, the advanced form of NAFLD, non-alcoholic steatohepatitis (NASH) with liver fibrosis increases mortality by approximately 70%, due to an increase in CVD mortality by approximately 300%. Chronic kidney disease (CKD) may be caused by NAFLD/NASH and it substantially increases CVD risk, especially in the presence of type 2 diabetes mellitus. Moreover, CKD may trigger NAFLD/NASH deterioration in a vicious cycle. NAFLD/NASH is also related to increased arterial stiffness (AS), an independent CVD risk factor that further raises CVD risk. Diagnosis of advanced liver fibrosis (mainly by simple non-invasive tests), CKD, and increased AS should be made early in the course of NAFLD and treated appropriately. Lifestyle measures and statin treatment may help resolve NAFLD/NASH and beneficially affect the CVD risk factors mentioned above.

Indexed as

BiopsyCardiovascular DiseasesCause of DeathComorbidityDiabetes Mellitus, Type 2HumansHydroxymethylglutaryl-CoA Reductase InhibitorsLife StyleLiver CirrhosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsPrognosisRenal Insufficiency, ChronicRisk AssessmentRisk FactorsRisk Reduction BehaviorHydroxymethylglutaryl-CoA Reductase InhibitorsArterial stiffnessCardiovascular diseaseChronic kidney diseaseInflammationLiver fibrosisNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisStatins

Identifiers

PMID26078558
PMCPMC4462722
OpenAlexW2418604408

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.